MY185516A - Compositions and methods for treating schizophrenia - Google Patents
Compositions and methods for treating schizophreniaInfo
- Publication number
- MY185516A MY185516A MYPI2017701998A MYPI2017701998A MY185516A MY 185516 A MY185516 A MY 185516A MY PI2017701998 A MYPI2017701998 A MY PI2017701998A MY PI2017701998 A MYPI2017701998 A MY PI2017701998A MY 185516 A MY185516 A MY 185516A
- Authority
- MY
- Malaysia
- Prior art keywords
- methods
- compositions
- treating schizophrenia
- compound
- isoindolin
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 201000000980 schizophrenia Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 abstract 2
- NZKANSJXJCILHS-UHFFFAOYSA-N 2-[[1-[2-(4-fluorophenyl)-2-oxoethyl]piperidin-4-yl]methyl]-3h-isoindol-1-one;dihydrate;hydrochloride Chemical compound O.O.Cl.C1=CC(F)=CC=C1C(=O)CN1CCC(CN2C(C3=CC=CC=C3C2)=O)CC1 NZKANSJXJCILHS-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462086691P | 2014-12-02 | 2014-12-02 | |
| US201562248071P | 2015-10-29 | 2015-10-29 | |
| PCT/US2015/062985 WO2016089766A1 (en) | 2014-12-02 | 2015-11-30 | Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY185516A true MY185516A (en) | 2021-05-19 |
Family
ID=54848909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2017701998A MY185516A (en) | 2014-12-02 | 2015-11-30 | Compositions and methods for treating schizophrenia |
Country Status (26)
| Country | Link |
|---|---|
| US (7) | US9458130B2 (enExample) |
| EP (2) | EP4063357B1 (enExample) |
| JP (4) | JP2018501217A (enExample) |
| KR (1) | KR102620681B1 (enExample) |
| CN (2) | CN111110677A (enExample) |
| AU (4) | AU2015355226B2 (enExample) |
| BR (1) | BR112017011555B1 (enExample) |
| CA (1) | CA2968977A1 (enExample) |
| CL (2) | CL2017001376A1 (enExample) |
| CO (1) | CO2017005498A2 (enExample) |
| DK (1) | DK3227273T3 (enExample) |
| EA (1) | EA201791226A1 (enExample) |
| ES (2) | ES2910528T3 (enExample) |
| HU (1) | HUE058212T2 (enExample) |
| IL (4) | IL301320B2 (enExample) |
| MX (1) | MX385586B (enExample) |
| MY (1) | MY185516A (enExample) |
| PE (1) | PE20171646A1 (enExample) |
| PH (1) | PH12017501007B1 (enExample) |
| PL (1) | PL3227273T3 (enExample) |
| PT (1) | PT3227273T (enExample) |
| SG (1) | SG11201704332YA (enExample) |
| TW (1) | TWI694069B (enExample) |
| UA (1) | UA122780C2 (enExample) |
| WO (1) | WO2016089766A1 (enExample) |
| ZA (1) | ZA201703481B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL301320B2 (en) | 2014-12-02 | 2024-11-01 | Minerva Neurosciences Inc | Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia |
| CN113694065A (zh) * | 2016-05-25 | 2021-11-26 | 田边三菱制药株式会社 | 用于治疗非精神分裂症患者中的阴性症状的组合物和方法 |
| JP2020525436A (ja) | 2017-06-21 | 2020-08-27 | ミネルバ・ニューロサイエンシズ・インコーポレイテッド | 胃耐性制御放出経口剤形 |
| MX2020002271A (es) | 2017-09-01 | 2020-10-05 | Ptc Therapeutics Mp Inc | Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas. |
| CN107721988A (zh) * | 2017-10-31 | 2018-02-23 | 无锡福祈制药有限公司 | 具有抗炎活性的异吲哚‑1‑酮类化合物 |
| EP3840835A1 (en) | 2018-08-21 | 2021-06-30 | Minerva Neurosciences, Inc. | Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection |
| TWI841545B (zh) * | 2018-12-12 | 2024-05-11 | 日商田邊三菱製藥股份有限公司 | 耐胃性控制釋放經口劑型 |
| US12441701B2 (en) * | 2019-06-28 | 2025-10-14 | Tapi Czech Industries S.R.O. | Solid state forms of roluperidone and salts thereof |
| IL298323B2 (en) | 2020-05-20 | 2023-10-01 | Univ Illinois | A method for treating lysosomal storage disease using histatin peptides |
| CN116251078B (zh) * | 2021-12-09 | 2025-12-19 | 河北以岭医药研究院有限公司 | 一种盐酸度洛西汀肠溶胶囊及其制备方法 |
| EP4479049B1 (en) | 2022-02-14 | 2025-12-17 | Minerva Neurosciences, Inc. | Use of roluperidone in preventing relapse in schizophrenia patients |
| WO2025090588A1 (en) | 2023-10-24 | 2025-05-01 | Minerva Neurosciences, Inc. | Roluperidone for the treatment of lysosomal storage disorders and their symptoms |
| WO2026035878A1 (en) * | 2024-08-07 | 2026-02-12 | Nimbus Saturn, Inc. | Hpk1 inhibitor formulations and methods of making the same |
| WO2026035872A1 (en) * | 2024-08-07 | 2026-02-12 | Nimbus Saturn, Inc. | Hpk1 inhibitor formulations and methods of making the same |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| ATE102482T1 (de) | 1988-01-21 | 1994-03-15 | Merrell Dow Pharma | Verwendung von 1,4-disubstituierten-piperidinyl- verbindungen zur herstellung eines arzneimittels zur behandlung von schlaflosigkeit. |
| EP0497843A4 (en) | 1989-10-27 | 1992-09-23 | The Du Pont Merck Pharmaceutical Company | (n-phthalimidoalkyl) piperidines |
| FR2797643B1 (fr) | 1999-08-17 | 2003-06-06 | Rhodia Chimie Sa | Utilisation composes terpeniques polyoxypropylenes/ polyoxyethylenes comme agent de degraissage de surfaces dures |
| NZ521576A (en) * | 2000-02-29 | 2005-06-24 | Mitsubishi Pharma Corp | Novel cyclic amide derivatives |
| WO2002076432A2 (en) | 2001-03-26 | 2002-10-03 | Novartis Ag | Pharmaceutical composition comprising a poorly water-soluble active ingredient, a surfactant and a water-soluble polymer |
| JP5281395B2 (ja) | 2005-06-06 | 2013-09-04 | メルク シャープ エンド ドーム リミテッド | 統合失調症の治療用のｇｌｙｔ１阻害剤としてのシクロヘキサンスルホニル誘導体 |
| CA2569776A1 (en) | 2006-02-17 | 2007-08-17 | Kos Life Sciences, Inc. | Low flush niacin formulation |
| GB2462611A (en) * | 2008-08-12 | 2010-02-17 | Cambridge Lab | Pharmaceutical composition comprising tetrabenazine |
| US8937900B2 (en) * | 2010-07-20 | 2015-01-20 | Qualcomm Incorporated | Enhancing pilot channel transmission in TD-SCDMA multicarrier systems using secondary carrier frequencies |
| WO2012012542A1 (en) * | 2010-07-20 | 2012-01-26 | Cyrenaic Pharmaceuticals, Inc. | Methods of use of cyclic amide derivatives to treat schizophrenia |
| RU2746871C2 (ru) * | 2010-07-20 | 2021-04-21 | Сиренейк Фармасьютикалз Инк. | Способы применения производных циклического амида для лечения опосредуемых сигма-рецепторами расстройств |
| EP2468264A1 (en) | 2010-12-27 | 2012-06-27 | Laboratorios Liconsa, S.A. | Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it |
| US9737531B2 (en) * | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| AU2012227936A1 (en) * | 2011-03-17 | 2013-10-17 | Lupin Limited | Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor |
| US10179776B2 (en) | 2014-06-09 | 2019-01-15 | Intra-Cellular Therapies, Inc. | Compounds and methods of use to treat schizophrenia |
| IL301320B2 (en) | 2014-12-02 | 2024-11-01 | Minerva Neurosciences Inc | Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia |
| CN113694065A (zh) | 2016-05-25 | 2021-11-26 | 田边三菱制药株式会社 | 用于治疗非精神分裂症患者中的阴性症状的组合物和方法 |
| JP2020525436A (ja) | 2017-06-21 | 2020-08-27 | ミネルバ・ニューロサイエンシズ・インコーポレイテッド | 胃耐性制御放出経口剤形 |
| EP3840835A1 (en) | 2018-08-21 | 2021-06-30 | Minerva Neurosciences, Inc. | Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection |
-
2015
- 2015-11-30 IL IL301320A patent/IL301320B2/en unknown
- 2015-11-30 PL PL15808314T patent/PL3227273T3/pl unknown
- 2015-11-30 WO PCT/US2015/062985 patent/WO2016089766A1/en not_active Ceased
- 2015-11-30 CA CA2968977A patent/CA2968977A1/en active Pending
- 2015-11-30 MY MYPI2017701998A patent/MY185516A/en unknown
- 2015-11-30 SG SG11201704332YA patent/SG11201704332YA/en unknown
- 2015-11-30 JP JP2017529388A patent/JP2018501217A/ja active Pending
- 2015-11-30 IL IL280052A patent/IL280052B2/en unknown
- 2015-11-30 CN CN202010012498.9A patent/CN111110677A/zh active Pending
- 2015-11-30 MX MX2017007065A patent/MX385586B/es unknown
- 2015-11-30 US US14/954,264 patent/US9458130B2/en active Active
- 2015-11-30 CN CN201580065471.3A patent/CN107567444A/zh active Pending
- 2015-11-30 UA UAA201706785A patent/UA122780C2/uk unknown
- 2015-11-30 EP EP22155504.8A patent/EP4063357B1/en active Active
- 2015-11-30 PH PH1/2017/501007A patent/PH12017501007B1/en unknown
- 2015-11-30 AU AU2015355226A patent/AU2015355226B2/en active Active
- 2015-11-30 HU HUE15808314A patent/HUE058212T2/hu unknown
- 2015-11-30 EA EA201791226A patent/EA201791226A1/ru unknown
- 2015-11-30 ES ES15808314T patent/ES2910528T3/es active Active
- 2015-11-30 PT PT158083147T patent/PT3227273T/pt unknown
- 2015-11-30 IL IL313572A patent/IL313572A/en unknown
- 2015-11-30 TW TW104139904A patent/TWI694069B/zh active
- 2015-11-30 PE PE2017000948A patent/PE20171646A1/es unknown
- 2015-11-30 DK DK15808314.7T patent/DK3227273T3/da active
- 2015-11-30 EP EP15808314.7A patent/EP3227273B1/en active Active
- 2015-11-30 BR BR112017011555-7A patent/BR112017011555B1/pt active IP Right Grant
- 2015-11-30 ES ES22155504T patent/ES3065087T3/es active Active
- 2015-11-30 KR KR1020177018088A patent/KR102620681B1/ko active Active
-
2016
- 2016-09-28 US US15/278,421 patent/US9730920B2/en active Active
-
2017
- 2017-05-17 IL IL252347A patent/IL252347B/en active IP Right Grant
- 2017-05-19 ZA ZA2017/03481A patent/ZA201703481B/en unknown
- 2017-05-30 CL CL2017001376A patent/CL2017001376A1/es unknown
- 2017-05-31 CO CONC2017/0005498A patent/CO2017005498A2/es unknown
- 2017-07-17 US US15/651,065 patent/US10258614B2/en active Active
-
2019
- 2019-03-01 US US16/290,234 patent/US10799493B2/en active Active
-
2020
- 2020-06-26 AU AU2020204286A patent/AU2020204286B2/en active Active
- 2020-07-06 JP JP2020116157A patent/JP7069253B2/ja active Active
- 2020-09-11 US US17/017,816 patent/US20210228561A1/en not_active Abandoned
-
2021
- 2021-01-07 CL CL2021000044A patent/CL2021000044A1/es unknown
- 2021-09-10 AU AU2021229240A patent/AU2021229240B2/en active Active
-
2022
- 2022-05-02 JP JP2022076280A patent/JP2022105159A/ja active Pending
-
2023
- 2023-02-17 US US18/111,072 patent/US20230201184A1/en not_active Abandoned
- 2023-11-01 AU AU2023258386A patent/AU2023258386B2/en active Active
-
2024
- 2024-10-02 JP JP2024173051A patent/JP2025004090A/ja active Pending
- 2024-11-27 US US18/961,748 patent/US20250195494A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021000044A1 (es) | Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil) piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia (divisional solicitud no. 1376-2017) | |
| MX381342B (es) | Compuestos terapeuticos inhibidores. | |
| TW201613872A (en) | IRAK4 inhibiting agents | |
| IL246875A0 (en) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahydropyridines as bace1 inhibitors for the treatment of Alzheimer's disease | |
| MX2017008518A (es) | Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih). | |
| PH12016501379A1 (en) | Azepane derivatives and methods of treating hepatitis b infections | |
| WO2015200680A8 (en) | Prmt5 inhibitors and uses thereof | |
| MX381417B (es) | Inhibidores de glucosidasa. | |
| NZ762034A (en) | Human plasma kallikrein inhibitors | |
| MX388957B (es) | Derivados del colano para uso en el tratamiento y/o prevencion de enfermedades en las que intervienen el fxr y el tgr5/gpbar1 | |
| EP4088724C0 (en) | ACETYLCHOLINESTERASE INHIBITORS FOR THE ORAL TREATMENT OF DERMATOLOGICAL CONDITIONS | |
| HRP20181698T1 (hr) | 2-amino-6-(difluormetil)-5,5-difluor-6-fenil-3,4,5,6-tetrahidropiridini kao inhibitori bace1 | |
| SG11201610217YA (en) | 2-(3-pyridinyl)-1h-benzimidazole derivative compound and medicine containing same | |
| PH12016501483A1 (en) | P-substituted asymmetric ureas and medical uses thereof | |
| MX382092B (es) | Compuestos heterocíclicos para el tratamiento de enfermedades. | |
| NZ730816A (en) | Quinoline carboxamides for use in the treatment of multiple myeloma | |
| EP2948441A4 (en) | PROCESS FOR PREPARATION OF 1- (4- (4- (3,4-DICHLOR-2-FLUORO-PHENYL AMINO) -7-METHOXYCHINAZOLINE-6-YLOXY) PIPERIDIN-1-YL) PROP-2-EN-1-ON | |
| MX389403B (es) | Inhibidor del receptor del factor de crecimiento de fibroblastos 4 (fgfr4) y metodo de preparacion y uso del mismo | |
| HK1227027A1 (en) | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer’s disease |